TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens

 
• By Joseph Haas

The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.

Tissue
TriSalus hopes its delivery technology can yield better outcomes in liver, pancreatic cancers

More from Strategy

More from Business